TITLE

Research & Markets: Brentuximab Vedotin - First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma)

PUB. DATE
August 2011
SOURCE
Biomedical Market Newsletter;8/23/2011, Vol. 21, p77
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses the need for drugs with enhanced toxicity and efficacy in treating Hodgkin and non-Hodgkin lymphoma. It says that the relapse rate for Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL) patients are 30% and 50%. It mentions the report "Brentuximab Vedotin: First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma)" which was added to the Research and Markets Ltd. offering.
ACCESSION #
65048775

 

Related Articles

  • Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease. Diehl, Volker; Franklin, Jeremy; Pfreundschuh, Michael; Lathan, Bernd; Paulus, Ursula; Hasenclever, Dirk; Tesch, Hans; Herrmann, Richard; Dorken, Bernd; Müller-Hermelink, Hans-Konrad; Dühmke, Eckhardt; Loeffler, Markus // New England Journal of Medicine;6/12/2003, Vol. 348 Issue 24, p2386 

    Background: Faced with unsatisfactory results of treatment for advanced Hodgkin's disease, we investigated three combinations of chemotherapy. Methods: From 1993 to 1998, 1201 eligible patients 15 to 65 years of age who had newly diagnosed Hodgkin's disease in unfavorable stage IIB or IIIA or...

  • Involved-Field Radiotherapy for Advanced Hodgkin's Lymphoma. Aleman, Berthe M.P.; Raemaekers, John M.M.; Tirelli, Umberto; Bortolus, Roberto; van 't Veer, Mars B.; Lybeert, Marnix L.M.; Keuning, Jo J.; Carde, Patrice; Girinsky, Théodore; van der Maazen, Richard W.M.; Tomšič, Radka; Vovk, Marjeta; van Hoof, Achilles; Demeestere, Geertrui; Lugtenburg, Pieternella J.; Thomas, José; Schroyens, Wilfried; De Boeck, Koenraad; Baars, Johanna W.; Kluin-Nelemans, Johanna C. // New England Journal of Medicine;6/12/2003, Vol. 348 Issue 24, p2396 

    Background: The use of involved-field radiotherapy after chemotherapy for advanced Hodgkin's lymphoma is controversial. Methods: We randomly assigned patients with previously untreated stage III or IV Hodgkin's lymphoma who were in complete remission after hybrid chemotherapy with...

  • Treatment decisions in a man with Hodgkin lymphoma and Guillian-Barré syndrome: a case report. Hughes, Caren L.; Yorio, Jeffrey T.; Kovitz, Craig; Oki, Yasuhiro // Journal of Medical Case Reports;2014, Vol. 8 Issue 1, p567 

    Introduction Guillain-Barre syndrome, or acute inflammatory demyelinating polyneuropathy, has been described in the presence of malignancies such as lymphoma. Guillain-Barre syndrome/acute inflammatory demyelinating polyneuropathy causes paresthesias and weakness, which can make the treatment of...

  • Antineoplastics.  // Reactions Weekly;10/21/2006, Issue 1124, p6 

    The article presents the case of a 31-year-old man who developed telangiectasia after receiving antineoplastic therapy with doxorubicin, bleomycin, vinblastine and dacarbazine for Hodgkin's disease. It references a study by M. Rodríguez-Martín et al, published in the September 2006 issue...

  • Four-cycle ABVD more toxic for older patients with Hodgkin's lymphoma.  // Hem/Onc Today;5/25/2013, Vol. 14 Issue 10, p31 

    The article discusses the findings of a study which revealed a significant dose reduction, delay in treatment, toxicity and treatment-associated mortality among patients aged at least 60 years with early-stage Hodgkins lymphoma who took four cycles of treatment with doxorubicin, bleomycin,...

  • Response to Intervention: Where Does the Gifted Child Fit? Johnsen, Susan // Gifted Child Today;Spring2008, Vol. 31 Issue 2, p5 

    The author reflects on the educational model Response to Intervention, which is part of the legislation Individuals with Disabilities Education Improvement Act of 2004. Response to Intervention is a process to help identify students at risk for learning disabilities. The author comments on the...

  • Doxorubicin liposomal.  // Reactions Weekly;2/4/2012, Issue 1387, p17 

    The article describes the case of a 37-year-old man developed palmoplantar erythrodysaesthesia (PPE) while receiving pegylated (PLD) and non-pegylated doxorubicin (NPLD) liposomal for Hodgkin's disease.

  • Cancer Chemotherapy Update. Solimando Jr., Dominic A.; Waddell, Aubrey // Hospital Pharmacy;Oct2009, Vol. 44 Issue 10, p858 

    The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy and to the agents, commercially available and...

  • ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. Fox, Christopher // Current Medical Literature: Leukemia & Lymphoma;2013, Vol. 21 Issue 3, p82 

    The article discusses research on the safety and efficacy of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) in older patients with classical Hodgkin lymphoma (cHL) who were treated within HD10 and HD11 trials. It references a study by B. Böll et al, published in a 2013 issue of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics